Company: GANX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001558370-25-005829
Chunk: 37

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 37
---
2024 through December 31, 2024. |

| (7) | Amount reflects medical, dental and vision insurance premium amounts paid by us on behalf of Mr. Mack, Mr. Alder, and Mr. Ballantyne, as well as life, long-term disability, short-term disability and accidental death and dismemberment insurance premiums paid by us on their behalf. |

| (8) | Mr. Fuggetta served as our Principal Financial Officer from February 21, 2024 to April 5, 2024 upon Mr. Ballantyne’s resignation from employment with the Company until the appointment of Mr. Mack as Chief Financial Officer on April 8, 2024. Upon Mr. Mack’s elevation to Chief Executive Officer as of January 6, 2025, Mr. Fuggetta was appointed Senior Vice President Finance and Principal Financial Officer. |

| (9) | Mr. Fuggetta received an annual base salary of ₣180,000 and non-equity incentive plan compensation of ₣21,000, which for reporting purposes has been converted into U.S. dollars at the 2024 average exchange rate of $1.136. Mr. Fuggetta received no additional compensation for his role as Principal Financial Officer from February 21, 2024 to April 5, 2024. |

| (10) | Mr. Fuggetta received an annual base salary of ₣150,000 and non-equity incentive plan compensation of ₣9,750, which for reporting purposes has been converted into U.S. dollars at the 2023 average exchange rate of $1.114. |

| (11) | Mr. Alder served as our Chief Executive Officer from September 20, 2022 until June 25, 2024. |

| (12) | Amount reflects an annual base salary of $525,000 pro-rated for Mr. Alder’s time as Chief Executive Officer from January 1, 2024 through June 25, 2024. |

| (13) | A portion of Mr. Alder’s stock awards were forfeited upon his termination from employment with the Company on June 25, 2024. |

| (14) | A portion of Mr. Alder’s option awards were forfeited upon his termination from employment with the Company on June 25, 2024. |

| (15) | Mr. Ballantyne served as our Chief